Published: May 30, 2025 Pfizer shared results from the BRAFTOVI BREAKWATER trial at ASCO 2025. The trial tested BRAFTOVI® (encorafenib) with cetuximab and mFOLFOX6 in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC). This post details the findings, based on a Pfizer press release. A video summary is also available. Advertisement What Is the BRAFTOVI BREAKWATER Trial? The BRAFTOVI … Continue reading BRAFTOVI BREAKWATER Trial: Survival Results at ASCO 2025